Myriad gets exclusive ex-US rights to sell Sividon's EndoPredict prognostic
Sividon Diagnostics GMBH granted Myriad Genetics GMBH exclusive rights to co-promote the EndoPredict cancer prognosis test outside of the US. The deal has an intial three-year term, and is renewable for two additional years.
- In Vitro Diagnostics
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Intra-Biotech Deal
- Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com